Matt Miksic
Stock Analyst at Barclays
(4.52)
Main Sectors:
38 Stocks
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
BSX Boston Scientific | Maintains: Overweight | 133 136 | 97.31 | 39.76% | 16 | Oct 2, 2025 | |
SENS Senseonics Holdings | Initiates Coverage On: Overweight | 2 | n/a | n/a | 1 | Aug 27, 2025 | |
HUMA Humacyte | Initiates Coverage On: Overweight | 4 | 2.1 | 66.67% | 1 | Aug 27, 2025 | |
LIVN LivaNova | Maintains: Equal-Weight | 55 58 | 53.37 | 8.68% | 8 | Aug 21, 2025 | |
PODD Insulet | Maintains: Equal-Weight | 266 300 | 309.12 | -2.95% | 9 | Aug 21, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 53 51 | 14.71 | 246.7% | 7 | Aug 8, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 41 36 | 23.86 | 50.88% | 18 | Aug 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 21 22 | 13.96 | 57.59% | 3 | Aug 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 24 21 | 15.15 | 38.61% | 14 | Jul 30, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 93 98 | 67.05 | 46.16% | 7 | Jul 30, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 95 | 77.07 | 23.26% | 24 | Jul 25, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 9 19 | 18.94 | 0.32% | 8 | Jul 22, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 165 176 | 188.64 | -6.7% | 13 | Jul 17, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 19 16 | 15.2 | 5.26% | 5 | Jun 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 261 241 | 193.58 | 24.5% | 1 | Jun 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 16 12 | 2.71 | 342.8% | 2 | May 5, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 684 635 | 452.35 | 40.38% | 7 | Apr 24, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 158 159 | 134.58 | 18.15% | 26 | Apr 17, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 103 | 60.48 | 70.3% | 15 | Feb 24, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 118 112 | 100.78 | 11.13% | 7 | Feb 10, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 418 443 | 370.6 | 19.54% | 21 | Feb 10, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 4.31 | 410.44% | 1 | Jan 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 109 | 97.7 | 11.57% | 15 | Nov 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 56 58 | n/a | n/a | 6 | Aug 4, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 15 | n/a | n/a | 1 | Dec 21, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 96 | 77.39 | 24.05% | 9 | May 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 100 | 67.03 | 49.19% | 4 | May 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 722 418 | 132.17 | 216.26% | 3 | May 4, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 31 28 | 15.95 | 75.55% | 2 | Mar 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 68 67 | 13.19 | 407.96% | 1 | Mar 1, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 4 | n/a | n/a | 4 | Jan 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | 7.06 | 6698.87% | 1 | Jan 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 87 | 14.8 | 487.84% | 14 | Nov 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 25 | 4.29 | 482.75% | 5 | Aug 10, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 200 160 | n/a | n/a | 2 | Nov 10, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 26 24 | n/a | n/a | 1 | Oct 10, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 9 | 7.21 | 24.83% | 1 | Dec 12, 2016 |